Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jul 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment option for patients with acute aortic syndrome, a serious condition affecting the aorta, which is the main artery that carries blood from the heart. The researchers want to find out how safe and effective the Castor single branch stent graft is for repairing the aorta in patients who do not have enough healthy tissue (less than 15mm) above the area needing repair.

To participate in this study, patients must be between 65 and 74 years old and diagnosed with a particular type of acute aortic syndrome called Stanford type B. They should have undergone a specific type of surgery called thoracic endovascular aortic repair using the Castor stent graft between June 2018 and June 2022. Unfortunately, patients with sufficient healthy tissue above the repair site, previous aorta repairs, or incomplete medical records cannot join the trial. If eligible, participants can expect close monitoring and follow-up to help assess the stent's performance and their overall health following the procedure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acute Stanford type B aortic syndrome who received thoracic endovascular aortic repair by meant of Castor single branch stent graft from June 2018 to June 2022
• Exclusion Criteria:
• • Patients with acute type B aortic syndrome with an adequate proximal landing zone (≥15mm)
• • Previous endovascular repair of the aorta
• • Patients with missing data and loss of follow-up